Citations

Clear

6273 citation(s) found for "To, Andrew".

Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network
McConnell, Michael J. , Moran, John V. , Abyzov, Alexej , Akbarian, Schahram , Bae, Taejeong , Cortés‐Ciriano, Isidro , Erwin, Jennifer A. , Fasching, Liana , Flasch, Diane A. , Freed, Donald , Ganz, Javier , Jaffe, Andrew E. , Kwon, Min‐Seok , Lodato, Michael A. , Mills, Ryan E. , Paquola, Apuã C.M. , Rodin, Rachel E. , Rosenbluh, Chaggai , Šestan, Nenad , Sherman, Maxwell A. , Shin, Joo Heon , Song, Saera , Straub, Richard E. , Thorpe, Jeremy , Weinberger, Daniel R. , Urban, Alexander E. , Zhou, Bo , Lehner, Thomas , Senthil, Geetha , Chess, Andrew , Courchesne, Eric , Gleeson, Joseph G. , Kidd, Jeffrey M. , Park, Peter J., Pevsner, Jonathan , Vaccarino, Flora M. , Network, Brain Somatic Mosaicism, Bekiranov, Stefan , Bohrson, Craig L. , Burbulis, Ian , Chronister, William D., Coppola, Gianfilippo , Daily, Kenneth , D’Gama, Alissa M. , Emery, Sarah B., Frisbie, Trenton J., Gao, Tianliuyun , Gulyás-Kovács, Attila, Haakenson, Mark F., Keil, Jason M. , Lam, Mandy M. , Mathern, Gary W. , Omberg, Larsson , Peters, Mette A. , Pochareddy, Sirisha , Pramparo, Tiziano , Sanavia, Tiziana , Wang, Meiyan , Wierman, Margaret E. , Wolpert, Matthew J., Woodworth, Mollie B. , Zhao, Xuefang , Zhou, Weichen , Kwan, Kenneth Y , Lodato, Michael A , Mills, Ryan E , Paquola, Apua C M , Rodin, Rachel E , Rosenbluh, Chaggai , Sestan, Nenad , Shin, Joo Heon , Song, Saera , Straub, Richard E , Urban, Alexander E , Zhou, Bo , Gage, Fred H , Lehner, Thomas , Senthil, Geetha , Chess, Andrew , Courchesne, Eric , Kidd, Jeffrey M , Pevsner, Jonathan , Vaccarino, Flora M , McConnell, Michael J. , Walsh, Christopher A. , Gleeson, Joseph G. , Network, Brain Somatic Mosaicism, Barton, Alison R. , Kopera, Huira C. , Lee, Eunjung A , Marquès‐Bonet, Tomàs , Moldovan, John B. , Oetjens, Matthew T. , Ratan, Aakrosh , Shi, Lei , Škarica, Mario , Wang, Jia , Wang, Yifan , Abyzov, Alexej , Bae, Taejeong , Akbarian, Schahram

Mayo Clinic

Science | April 27, 2017 | Volume: 356 | Issue: 6336 | Pages: No page available

10.1126/science.aal1641 | PMID 28450582 Get It

Single-cell diversity in the brain The cells that make up an organism may all start from one genome, but somatic mutations mean that somewhere along the line of development, an organism's individual cellular genomes diverge. McConnell et al. review the implications and causes of single-cell genomic diversity for brain function. Somatic mutations caused by mobile genetic elements or errors in DNA repair may underlie certain neuropsychiatric disorders. Science , this issue p. eaal1641
Subarachnoid and intraperitoneal hemorrhage secondary to segmental arterial mediolysis: A case report and review of the literature
Welch, Brian T. , Brinjikji, Waleed , Stockland, Andrew H., Lanzino, Giuseppe

Mayo Clinic

Interventional Neuroradiology | April 26, 2017 | Volume: 23 | Issue: 4 | Pages: 378-381

10.1177/1591019917703074 | PMID 28443482 Get It

Background Segmental arterial mediolysis (SAM) is an uncommon or underdiagnosed arteriopathy that presents with life-threatening hemorrhage. SAM can affect the intracranial, spinal, and visceral arteries, with reported cases of concomitant intracranial and visceral hemorrhage. Case description We present the case of a 61-year-old male with concurrent subarachnoid and intraperitoneal hemorrhage caused by simultaneously bleeding posterior spinal artery and splenic artery pseudoaneurysms. The posterior spinal artery pseudoaneurysms were treated with selective injection of polyvinyl alcohol particles into the posterior spinal artery, while the splenic artery pseudoaneurysm was treated with Gelfoam embolization. The constellation of imaging, clinical, and laboratory features led to a presumptive diagnosis of SAM, which remains the only reported cause of concurrent neurovascular and visceral artery aneurysm rupture. Conclusion SAM is a key diagnostic consideration in cases of concomitant intracranial, spinal, and visceral artery aneurysm rupture.
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
LaPlant, Betsy, Call, Timothy G. , Leis, José F., He, Rong , Wiseman, Gregory A., Lin, Yi , Asmus, Erik, Nowakowski, Grzegorz S. , Conte, Michael, Bowen, Deborah A., Aitken, Casey N., Dyke, Daniel L. Van , Greipp, Patricia T. , Wu, Xiaosheng , Secreto, Charla, Tian, Shulan , Braggio, Esteban , Wellik, Linda, Micallef, Ivana N. , Viswanatha, David S., Yan, Huihuang , Chanan‐Khan, Asher , Ansell, Stephen M. , LaPlant, Betsy R, Chanan-Khan, Asher A., Ding, Wei , Parikh, Sameer A. , Shanafelt, Tait D. , Sinha, Sutapa , Le‐Rademacher, Jennifer , Feldman, Andrew L. , Habermann, Thomas M. , Witzig, Thomas E. , Liu, Xin , Zhang, Henan , Kay, Neil E. , Dong, Haidong , Braggio, Esteban , Greipp, Patricia T , Lin, Yi

Mayo Clinic

Blood | April 20, 2017 | Volume: 129 | Issue: 26 | Pages: 3419-3427

10.1182/blood-2017-02-765685 | PMID 28424162 Get It

Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.
Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology
Montazerhodjat, Vahid, Chaudhuri, Shomesh E. , Sargent, Daniel J. , Lo, Andrew W.

Mayo Clinic

JAMA Oncology | April 18, 2017 | Volume: 3 | Issue: 9 | Pages: e170123

10.1001/jamaoncol.2017.0123 | PMID 28418507 Get It

Cardiac autonomic control and complexity during sleep are preserved after chronic sleep restriction in healthy subjects
Covassin, Naima , Calvin, Andrew D. , Singh, Prachi , Bukartyk, Jan , Wang, Shiang, Montano, Nicola , Tobaldini, Eleonora, Calvin, Andrew, Tobaldini, Eleonora , Wang, Shiang, Somers, Virend K. , Singh, Prachi , Calvin, Andrew D , Montano, Nicola

Mayo Clinic

Physiological Reports | April 13, 2017 | Volume: 5 | Issue: 7 | Pages: e13197

10.14814/phy2.13197 | PMID 28408635 Get It

Zoledronic Acid Dosing Interval for Metastatic Cancer—Reply
Himelstein, Andrew L., Loprinzi, Charles L. , Shapiro, Charles L.

Mayo Clinic

JAMA | April 11, 2017 | Volume: 317 | Issue: 14 | Pages: 1478

10.1001/jama.2017.2566 | PMID 28399247 Get It

Brain‐responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy
Geller, Eric B., Skarpaas, Tara L. , Barkley, Gregory L., Bazil, Carl W., Berg, Michael J. van den, Bergey, Gregory K. , Cash, Sydney S. , Cole, Andrew J. , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, James, Fountain, Nathan B. , Goldman, Alicia, Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamar, Hirsch, Lawrence J. , Jobst, Barbara C. , King‐Stephens, David , Labar, Douglas, Leiphart, James W., Marsh, W. Richard , Meador, Kimford J. , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Shields, Donald C. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul C. Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Cicora, Kathy, Sun, Felice T., Morrell, Martha J. , Cole, Andrew J , Noe, Katherine H. , Gross, Robert E. , Goodman, Robert , Berg, Michael J., Edwards, Jonathan , Smith, Michael C. F. , Worrell, Gregory A. , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 11, 2017 | Volume: 58 | Issue: 6 | Pages: 994-1004

10.1111/epi.13740 | PMID 28398014 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of mesial temporal lobe (MTL) brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of mesial temporal lobe origin.MethodsSubjects with mesial temporal lobe epilepsy (MTLE) were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events.ResultsThere were 111 subjects with MTLE; 72% of subjects had bilateral MTL onsets and 28% had unilateral onsets. Subjects had one to four leads placed; only two leads could be connected to the device. Seventy‐six subjects had depth leads only, 29 had both depth and strip leads, and 6 had only strip leads. The mean follow‐up was 6.1 ± (standard deviation) 2.2 years. The median percent seizure reduction was 70% (last observation carried forward). Twenty‐nine percent of subjects experienced at least one seizure‐free period of 6 months or longer, and 15% experienced at least one seizure‐free period of 1 year or longer. There was no difference in seizure reduction in subjects with and without mesial temporal sclerosis (MTS), bilateral MTL onsets, prior resection, prior intracranial monitoring, and prior vagus nerve stimulation. In addition, seizure reduction was not dependent on the location of depth leads relative to the hippocampus. The most frequent serious device‐related adverse event was soft tissue implant‐site infection (overall rate, including events categorized as device‐related, uncertain, or not device‐related: 0.03 per implant year, which is not greater than with other neurostimulation devices).SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including patients with unilateral or bilateral MTLE who are not candidates for temporal lobectomy or who have failed a prior MTL resection.
Lymphoma classification update: B-cell non-Hodgkin lymphomas
Jiang, Manli, Feldman, Andrew L. , Bennani, N. Nora , Feldman, Andrew L

Mayo Clinic

Expert Review of Hematology | April 11, 2017 | Volume: 10 | Issue: 5 | Pages: 405-415

10.1080/17474086.2017.1318053 | PMID 28395545 Get It

Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy
Yang, David Y. , Thompson, R. Houston, Zaid, Harras B. , Lohse, Christine M. , Boorjian, Stephen A. , Leibovich, Bradley C. , Cheville, John C. , Tollefson, Matthew K. , Rule, Andrew D. , Yang Md, David

Mayo Clinic

Journal of Urology | April 8, 2017 | Volume: 198 | Issue: 4 | Pages: 795-802

10.1016/j.juro.2017.04.016 | PMID 28396181 Get It

Brain‐responsive neurostimulation in patients with medically intractable seizures arising from eloquent and other neocortical areas
Jobst, Barbara C. , Kapur, Ritu, Barkley, Gregory L., Bazil, Carl W., Berg, Michel J., Bergey, Gregory K. , Boggs, Jane , Cash, Sydney S. , Cole, Andrew J. , Duchowny, Michael , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, A. James, Fountain, Nathan B. , Geller, Eric B., Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamr A., Hirsch, Lawrence J. , King‐Stephens, David , Labar, Douglas, Marsh, W. Richard , Meador, Kimford J. , Miller, Ian , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Olejniczak, Piotr W., Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Skarpaas, Tara L. , Morrell, Martha J. , Noe, Katherine H. , Edwards, Jonathan C. W. , Goldman, Alica M. , Goodman, Robert , Gross, Robert E. , Smith, Michael C. F. , Worrell, Gregory A. , Cole, Andrew J , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 7, 2017 | Volume: 58 | Issue: 6 | Pages: 1005-1014

10.1111/epi.13739 | PMID 28387951 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of neocortical origin.MethodsPatients with partial seizures of neocortical origin were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events. Additional analyses considered safety and seizure reduction according to lobe and functional area (e.g., eloquent cortex) of seizure onset.ResultsThere were 126 patients with seizures of neocortical onset. The average follow‐up was 6.1 implant years. The median percent seizure reduction was 70% in patients with frontal and parietal seizure onsets, 58% in those with temporal neocortical onsets, and 51% in those with multilobar onsets (last observation carried forward [LOCF] analysis). Twenty‐six percent of patients experienced at least one seizure‐free period of 6 months or longer and 14% experienced at least one seizure‐free period of 1 year or longer. Patients with lesions on magnetic resonance imaging (MRI; 77% reduction, LOCF) and those with normal MRI findings (45% reduction, LOCF) benefitted, although the treatment response was more robust in patients with an MRI lesion (p = 0.02, generalized estimating equation [GEE]). There were no differences in the seizure reduction in patients with and without prior epilepsy surgery or vagus nerve stimulation. Stimulation parameters used for treatment did not cause acute or chronic neurologic deficits, even in eloquent cortical areas. The rates of infection (0.017 per patient implant year) and perioperative hemorrhage (0.8%) were not greater than with other neurostimulation devices.SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including adults with seizures of neocortical onset, and those with onsets from eloquent cortex.